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Introduction
Integrins are heterodimeric transmembrane cell surface recep-
tors that mediate connections between cells or between cells 
and the ECM (Hynes, 2002). Integrins control many fundamen-
tal aspects of cell behavior through their ability to transduce 
signals bidirectionally across the cell membrane. This transfer 
is manifested in global conformational changes that specify the 
activation state and ligand-binding affinity of the receptor.   
Currently three separate integrin conformational classes have 
been identified: inactive, active (or primed), and ligand bound, 
and it is has been proposed that these states correspond to a bent 
conformation (seen in crystal structures; Xiong, et al., 2001; 
Zhu et al., 2008), an extended form with a closed headpiece, 
and an extended form with an open headpiece, respectively 
(Takagi et al., 2002).
The opening of the headpiece is predicted to induce sepa-
ration of the integrin subunit legs that allows intracellular 
signaling molecules to bind during the process of outside-in 
signaling (Mould et al., 2003a,b; Xiao et al., 2004; Puklin- 
Faucher et al., 2006). Although there are many images that show 
the extracellular domains of integrins with splayed legs (Takagi   
et al., 2002; Nishida, et al., 2006), information regarding the   
extent to which this occurs in vivo is more sparse and limited to 
integrins on nonadherent cells (Kim et al., 2003; Partridge,   
et al., 2005; Lefort et al., 2009).
There is also accumulating evidence to suggest that inte-
grin need not be fully extended to bind ligand. This includes 
structural (Adair et al., 2005) and biochemical data (Calzada   
et al., 2002), as well as biophysical fluorescent resonance   
energy transfer (FRET) measurements that have attempted to 
measure conformational changes on the cell surface in response 
to different agonists (Chigaev et al., 2003, 2007; Coutinho et al., 
2007). These experiments suggest a level of complexity in inte-
grin conformational changes not revealed by the structural snap-
shots so far obtained and pose further questions as to exactly 
how integrin conformation relates to function and how these 
changes are coupled.
In addition, the vast majority of structural and modeling 
data have been obtained using constructs of 2 (Beglova et al., 
2002; Shi et al., 2007) and 3 (Iwasaki et al., 2005; Rocco et al., 
2008) integrins whose activity has to be strictly controlled in vivo 
and that are mainly expressed on nonadherent cells such as 
leukocytes and platelets. Therefore, it is still not known whether 
similar conformational changes apply to all integrin families; 
I
ntegrins undergo global conformational changes that 
specify their activation state. Current models portray 
the inactive receptor in a bent conformation that upon 
activation converts to a fully extended form in which the 
integrin subunit leg regions are separated to enable   
ligand binding and subsequent signaling. To test the   
applicability of this model in adherent cells, we used a 
fluorescent resonance energy transfer (FRET)–based ap-
proach, in combination with engineered integrin mutants 
and  monoclonal  antibody  reporters,  to  image  integrin 
51 conformation. We find that restricting leg separa-
tion causes the integrin to adopt a bent conformation that 
is unable to respond to agonists and mediate cell spread-
ing. By measuring FRET between labeled 51 and the 
cell membrane, we find extended receptors are enriched 
in focal adhesions compared with adjacent regions of the 
plasma membrane. These results demonstrate definitely 
that  major  quaternary  rearrangements  of  1-integrin 
subunits occur in adherent cells and that conversion from 
a bent to extended form takes place at focal adhesions.
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Figure 1.  Preventing leg separation at the calf-2/TD interface of soluble 51-Fc induces bending of the molecule. (A) Diagram showing the approxi-
mate location of the epitopes of the anti-5 and -1 antibodies used in this study. The reagents include the activating anti-1 mAbs 12G10 (A domain; 
Mould et al., 1995), HUTS4 (hybrid domain; Mould et al., 2003a), 8E3 (PSI domain; Mould et al., 2005), 9EG7 (I-EGF2-4; Bazzoni et al., 1995), and 
the activating anti-5 SNAKA51 (calf1-calf2; Clark et al., 2005). The nonfunction perturbing anti-1 K20 (I-EGF region; Amiot et al., 1986) and anti-5 
mAb11 (calf1-calf2; LaFlamme et al., 1992) and VC5 (-propeller; Tran Van Nhieu and Isberg, 1993) are also highlighted. The approximate location of 
the engineered inter-subunit disulphide bond is indicated. (B) Homology model of 51 in the region defined by dotted lines in A. The homology model 
was built based on an alignment against the IIb3 crystal structure (PDB 3FCS; Zhu et al., 2008), using the same procedures as described previously 
(Mould et al., 2002). The 5 calf-2 domain is in blue and I-EGF4 and TD of the 1 subunit are in red. The residues selected for mutation to cysteine to 893 Integrin extension at focal adhesions • Askari et al.
to WT and LT 51-Fc with the exception of the anti-1 
mAb 9EG7 (Fig. 1 D). Antibody binding was restored upon 
treatment with dithiothreitol (DTT), confirming that the epi-
tope had not been compromised by the mutation. These data in-
dicate that restraining the integrin legs induces a conformation 
of 51-Fc that masks the 9EG7 epitope. The binding site 
for 9EG7 lies within the integrin-EGF (I-EGF)–like repeats   
2–4 of 1 (Bazzoni et al., 1995), but to assess the effect on   
integrin conformation more precisely, mutations were per-
formed in WT 1-Fc to pinpoint the precise epitope. 9EG7 was 
raised against mouse 1 in a rat background but cross-reacts 
with the human molecule (Lenter et al., 1993); therefore, resi-
dues that were the same in human and mouse 1 but different 
to rat within I-EGF 2–4 were selected for mutation. Only two 
residues fulfilled these criteria, D522 and S582 in the human 
molecule. These residues were mutated to the corresponding 
residues of the rat sequence (glutamate and threonine, respec-
tively) in human 1-Fc, expressed with 5-Fc, and tested for 
binding of 9EG7 in Fc-capture ELISA. D522E totally abol-
ished 9EG7 binding, whereas S582T had no effect (Fig. 1 E). 
Thus, the epitope for 9EG7 was pinpointed to D522 in I-EGF-2 
of the 1-subunit.
A homology model of 51 revealed that D522 is located 
in the genu or knee region of the molecule, shielded by the 
-subunit on one side and the -subunit on the other when the   
receptor is in a bent conformation, making it inaccessible to 
the antibody (Fig. 1 F). Therefore, we infer that restraining the 
legs of 51-Fc at the calf-2/TD interface causes the integrin 
to adopt a bent conformation that masks the 9EG7 epitope, and 
that  binding  of  this  antibody  therefore  reports  the  extended   
conformations of 1-integrins. Currently, there are no structural 
data and very limited biochemical evidence to indicate bending 
in 1-integrins (Mould et al., 2005); however, the data obtained 
with 9EG7 strongly suggest that 51 can adopt a bent confor-
mation if the membrane-proximal extracellular interface is held 
in close association.
Restraining leg separation of soluble  
51-Fc at the calf-2/TD interface  
impairs ligand binding and abrogates the 
ability of activating antibodies to stimulate 
ligand binding
As the bent conformation of integrins is generally accepted to 
have low affinity for ligand, the effect of restraining the legs of 
51 on ligand binding was studied using a 50-kD recombinant 
indeed, there is a striking paucity of conformational information 
for the ubiquitously expressed 1-integrins that are subjected to 
greater tensions when mediating cell–ECM adhesion, but whose 
activity is less likely to be rigidly modulated.
In this study, we have used a variety of approaches to   
investigate  conformational  changes  in  the  fibronectin  (FN)   
receptor 51. We found that restricting leg separation with an 
inter-subunit disulphide bond caused the integrin to adopt a bent 
conformation that was unable to respond to agonists due to a 
concomitant reduction of movements in the -subunit leg that 
accompany receptor activation. Cells expressing this mutated 
integrin were unable to spread and form focal adhesions (FAs) 
on  FN.  Using  fluorescence  lifetime  imaging  microscopy 
(FLIM)–based FRET analysis, we found that wild-type (WT) 
51 in the FA of cells spread on FN was in an extended form 
compared with unligated receptor. These results extend our 
understanding  of  integrin  structure–function  relationships  to 
1-integrins on adherent cells and underscore the importance of 
integrin extension and leg separation in vivo.
Results
Preventing leg separation at the calf-2/TD 
interface of soluble 51-Fc induces 
bending of the molecule
Conversion of an integrin from an inactive to a ligand-bound 
state is predicted to involve a separation of the leg regions of the 
receptor (Zhu et al., 2007). To examine the importance of leg 
separation to the function of the FN receptor 51, we used a 
previously described, recombinant-soluble 51-Fc fusion 
protein (Coe et al., 2001) to engineer a construct in which the 
membrane-proximal 51 calf-2/-tail domain (TD) interface 
was constrained by introduction of a disulphide bond between 
the - and -subunits to form a potential locked-together (LT) 
integrin (Fig. 1, A and B). Lysine-758 in the calf-2 region of 
5-Fc, and glycine-618 in the TD of 1-Fc were chosen for 
mutation as they are the equivalent residues to those introduced 
in v3 to produce a similarly constrained receptor (Kamata 
et al., 2005). Successful production of the LT protein was con-
firmed by SDS-PAGE after removal of the Fc domain from the 
1-subunit (Fig. 1 C).
A panel of stimulatory anti-5 and -1 monoclonal anti-
bodies (mAbs), with epitopes spanning the entire integrin extra-
cellular domain, was used to examine the conformation of the 
mutated receptor. All the antibodies tested bound equally well 
form the inter-subunit disulphide bond, Lys758 in 5 and Gly618 in 1, are shown in CPK form in green. (C) WT or LT 51-Fc was purified from culture 
supernatant and then incubated with Tobacco Etch Virus protease (TEV) to remove the Fc domain from the -subunit. 3–8% SDS-PAGE gel showing 51-Fc 
dimer (black arrowhead, Mr 300 kD) that dissociates upon TEV protease treatment in WT (lane 2) but not LT (lane 4) integrin. Reduction of the disulphide 
bond separates LT into its two subunits (gray arrowhead, 5-Fc Mr 145 kD, 1-Fc 140 kD). The band at 150 kD in nonreduced samples is contaminat-
ing bovine Ig from culture medium. This dissociates upon reduction into its component 50- and 25-kD subunits not included in the figure. Numbers to the left 
of the gel indicate the position of Mr markers. (D) WT or LT 51-Fc was captured onto anti–human Fc-coated ELISA plates and the binding of activating 
anti-5 (SNAKA51) and anti-1 (12G10, HUTS4, 8E3, and 9EG7) antibodies to WT (gray bars) and LT (black bars) 51-Fc compared with nonfunction 
perturbing anti-5 (mAb11) and anti-1 (K20) in the presence of 1 mM each of Ca
2+ and Mg
2+. DTT was included at 250 µM where indicated. Error bars 
show ±SD of three separate experiments. (*, P = 0.001; t test). (E) Binding of K20 (gray bars) or 9EG7 (black bars) to WT 51-Fc, 51(S582T)-Fc, and 
51(D522E)-Fc. Error bars indicate ±SD of three separate experiments. (F) Homology model of extracellular domain of 51 showing the position of the 
9EG7 epitope at D522 in I-EGF2, which is colored green with D522 represented in CPK form. For clarity, the integrin headpiece (5 -propeller and A 
domain) is not included. The model was prepared as in panel B.
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fragment of FN comprising type III repeats 6–10 (50K). Neither 
WT  nor  LT  51-Fc  bound  ligand  in  the  presence  of  Ca
2+  
and Mg
2+ (Fig. 2 B). However, in the presence of Mn
2+, WT 
51-Fc exhibited high ligand binding that was significantly   
reduced  (P < 0.001)  but not completely abolished in the  LT   
receptor (Fig. 2 A). Treatment with DTT fully restored ligand 
binding capability.
Activating  anti-integrin  antibodies  exert  their  effect  by   
inducing or stabilizing an active conformer to increase ligand 
binding (Humphries, 2004). The effect of restraining the legs on 
ligand binding in the presence of stimulatory mAbs was there-
fore studied to investigate how conformational changes leading 
from inactive to active receptor are coupled. These experiments 
were performed in the presence of Ca
2+ and Mg
2+ where consti-
tutive ligand binding is low, thus allowing the full activating   
effect  of  the  antibodies  to  be  observed. The  nonfunction- 
perturbing mAbs K20 (1) and mAb11 (5) had no effect on   
ligand binding to either the WT or LT construct and, as ex-
pected, the stimulatory anti-1 (12G10, HUTS4, 8E3, and 
9EG7)  and  anti-5  (SNAKA51)  mAbs  all  enhanced  ligand 
binding to the WT 51-Fc (Fig. 2 B). However, clear differences 
were apparent in the ability of the antibodies to augment 50K 
binding to LT 51-Fc. The function of 12G10 was not im-
paired, but HUTS4, 8E3, and 9EG7 showed a decreased abil-
ity to enhance 50K binding that correlated with the distance 
of their epitopes from the disulphide bond between the - and 
-subunit (Fig. 1 A). In addition, the ability of SNAKA51, the epi-
tope for which lies in the 5 calf-1/calf-2 domain (Clark et al., 
2005), to stimulate 50K binding to LT 51-Fc was also mark-
edly reduced. These results demonstrate that the formation of a 
disulphide lock between the 5 calf domain and the 1 TD 
compromised induction of the related allosteric shape changes 
that equate to the high affinity ligand-bound conformation. Thus, 
these changes are dependent on integrin leg separation.
An outward movement of the hybrid domain, producing 
the open integrin headpiece, is a hallmark of high affinity inte-
grin and is reported in 1-integrins by the HUTS4 antibody that 
binds to the inner face of the domain (Mould et al., 2003a). The 
above results suggest that restraining integrin leg movement   
results in a reduced ability of this region to take on its high   
affinity, open position. To gain further information on shape 
changes in the LT receptor, the effects of various agonists such 
as ligand (50K), and the stimulatory antibodies 12G10 (anti-1) 
and SNAKA51 (anti-5), on the binding of HUTS4 to WT and 
LT 51-Fc were examined. Both 50K and 12G10 caused an 
increase in the binding of HUTS4 to WT 51-Fc that was   
almost completely abrogated in the LT integrin (Fig. 2 C),   
suggesting that restraining leg separation reduces hybrid swing-
out. This result further implies that leg separation is directly 
coupled to hybrid domain movement.
In contrast, binding of SNAKA51 was unable to stimulate 
HUTS4  binding  in  the WT  integrin  (Fig.  2  C). This  would   
Figure 2.  Restraining leg separation of soluble 51-Fc at the calf-2/TD 
interface impairs ligand binding and abrogates the ability of activating 
antibodies to stimulate ligand binding. (A) Fc-capture ELISA showing bind-
ing of FN fragment (type III repeats 6–10; 50K) to WT (gray bars) and LT 
51-Fc (black bars) before and after treatment with 250 µM DTT in the 
presence of 1mM Mn
2+. (B) Fc-capture ELISA showing binding of 50K to 
WT (gray bars) and LT (black bars) 51-Fc together with activating anti-
5 (SNAKA51) and anti-1 (12G10, HUTS4, 8E3, and 9EG7) antibodies, 
compared with nonfunction-perturbing anti-5 (mAb11) and anti-1 (K20) 
in the presence of 1 mM each of Ca
2+ and Mg
2+ (*, P = 0.001; t test). 
(C) Fc-capture ELISA showing the effects of various 51 agonists on the 
binding of HUTS4 to WT and LT 51-Fc. Error bars indicate ±SD for three 
separate experiments. *, P < 0.001; t test.
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suggest that SNAKA51 exerts its stimulatory effect, at least on 
the soluble, recombinant 51-Fc, by inducing a destabiliza-
tion of the leg regions that is not sufficient to induce hybrid 
swing-out. Surprisingly, in the LT construct, SNAKA51 ap-
peared to inhibit the binding of HUTS4, lending weight to the 
hypothesis that the LT integrin is bent, because only in this con-
formation would the epitopes of these antibodies be close 
enough to affect each other’s binding. Taken together, these re-
sults indicate that restraining the integrin legs inhibits the effect 
of agonists and interferes with structural rearrangements associ-
ated with the switch from inactive to active receptor. Therefore, 
leg separation and hybrid movement are intimately associated.
Epitope expression on cell surface integrin
A series of experiments were then conducted to extend the find-
ings obtained with soluble receptors to those expressed at the 
cell surface. Using flow cytometry, the level of binding of acti-
vating anti-5 and anti-1 antibodies was used to assess 51 
conformation on the cell surface of human foreskin fibroblasts 
(HFFs) under conditions promoting low (in the presence of 
Ca
2+ and Mg
2+) and high (in Mn
2+ with or without 50K) affinity   
integrin (Table I). The binding of 9EG7 to resting cells was signifi-
cantly above background levels (mean fluorescence intensity 
[MFI] 34.33), indicating the presence of primed 1-integrin on 
the cell surface.
The binding of SNAKA51 was low, but increased signifi-
cantly with the addition of Mn
2+ and ligand (MFI from 3.24 to 
12.68), indicating that this antibody preferentially binds to the 
ligand-bound form of the integrin and is consistent with the idea 
that a conformational change in the leg regions, which may in-
volve leg separation, induced by ligand increases the exposure of 
the SNAKA51 epitope. Therefore, we conclude that SNAKA51 
binds to a ligand-bound conformer in which the integrin legs are 
most likely separated and that SNAKA51 activates integrin by 
stabilizing a conformer that is competent to bind ligand.
FLIM-based FRET analysis of conformation 
differences of integrin 51 in HFF cells 
spread on FN
Having surveyed the conformation of 51 on cells in suspen-
sion, we next examined how integrin conformation is affected 
when cells spread and force is generated on the integrin–ligand 
complex at sites of adhesion complex formation. To address 
how integrin conformation varies with location, and in particu-
lar to assess the degree of extension of 51 present in adhe-
sion complexes in comparison to adjacent regions of the cell 
membrane,  whole  cells  were  imaged  using  time-correlated   
single photon counting (TCSPC) FLIM-based FRET analysis. 
FRET is a phenomenon by which the excited-state energy of an 
optically excited molecule (donor) is transferred to a neigh-
boring molecule (acceptor) nonradiatively via intermolecular   
dipole coupling (Lakowicz, 1983). FRET is therefore extremely 
sensitive to short intermolecular distances (<10 nm), with the 
efficiency of FRET varying as the inverse sixth power with   
distance  (Stryer  and  Haugland,  1967).  TCSPC-FLIM-FRET   
directly measures the time between the absorption and emission 
of individual photons in the FRET donor fluorophores and has 
the advantage of providing quantitative results largely free   
from artifacts such as photobleaching and radiative transfer   
(Martin-Fernandez et al., 2002).
The 51 headpiece on HFF cells was labeled with an 
Alexa Fluor 546–tagged Fab fragment of a nonfunction perturb-
ing  anti-5  mAb VC5  and  the  cell  membrane  stained  with 
C18DiD. An overlap between the emission spectrum of Alexa 
546 and the absorption spectrum of C18DiD allows these two 
dyes to act as a FRET pair. A shortening of the donor (VC5-
Fab-Alexa 546) lifetime from that observed in the absence of 
acceptor (C18DiD) was used to quantify FRET between the two 
fluorophores. To eliminate the possibility that rigidity in the ori-
entation of the dye molecules could account for any variations 
in FRET efficiencies, the steady-state fluorescence anisotropy 
of C18DiD in lipid vesicles was measured. This was found to be 
0.154, whereas the maximum possible value expected for static 
dye molecules is 0.4 (Lakowicz, 1983), indicating that the   
acceptors used were free to rotate and sample a large number of 
orientations  within  the  lifetime  of  the  donor. Therefore,  the 
measured FRET efficiencies depended only upon the donor and 
acceptor separation distance and the density of acceptors in the 
membrane (Stryer and Haugland, 1967; Haas et al., 1978).
The donor (VC5-Fab-Alexa 546) was found to label both 
membrane and adhesion complexes in cells expressing both WT 
and LT 51 equally, showing that the access of the Fab to its 
Table I. Flow cytometry analysis of integrin conformation
MFI
Integrin subunit Antibody CaMg
2+ Mn
2+ Mn
2+ + 50K
1 K20
a 143.87 138.17 141.56
12G10 59.49 102.35 95.81
HUTS4 4.85 19.04 26.94
8E3 5.48 6.24 6.86
9EG7 34.33 61.02 74.30
5 mab11
a 25.28 26.83 23.42
SNAKA51 3.24 6.21 12.68
Flow cytometry was used to measure the binding of anti-51 antibodies to HFF cells under conditions promoting low (in the presence of 1 mM each Ca
2+ and Mg
2+) 
and high affinity (in the presence of Mn
2+ with or without the addition of 50K ligand). The non-function perturbing antibodies K20 (anti-1) and mAb11 (anti-5) were 
used to estimate total expression of each subunit. The results are expressed as mean fluorescence intensity (MFI) with background binding levels of normal rat or mouse 
IgG subtracted, and are representative of three separate experiments.
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(Wennerberg et al., 1996). To facilitate visualization of each 
subunit, 5 was tagged with CFP and 1 with YFP at their   
C termini. Western blot analysis confirmed formation of the LT 
integrin, which dissociated upon reduction into its component 
subunits (Fig. 4 A).
Flow cytometric analysis was first performed to assess the 
expression of LT and WT 51 on the cell surface. Both recep-
tors were expressed to a similar degree, as measured by almost 
equal levels of K20 binding (Fig. S3; MFI 105.78 for WT and 
108.89 for LT). Binding of 9EG7, however, was significantly 
reduced in cells expressing LT integrin compared with WT 
(MFI 6.95 and 31.92, respectively), but this was restored after 
treatment of the cells with 250 µM DTT (MFI 25.42). These   
results confirm that LT 51 was expressed on the cell surface 
in a bent conformation.
Cells expressing WT 5CFP1YFP spread and produced 
well-formed adhesion complexes on FN that were 9EG7 posi-
tive, indicating a high affinity, extended state. Cells expressing 
LT 5CFP1YFP also spread and produced clusters of 1 that 
were less well formed than WT and had a significantly smaller 
mean area (7.73 ± 3.69 µm
2 compared with 14.86 ± 9.64 µm
2 for 
cells expressing WT 51; P < 0.001; Fig. 4 B). Importantly, these 
clusters had significantly reduced binding of 9EG7 (Fig. 4 C), 
suggesting that, as with soluble 51, preventing leg separation 
caused the integrin to adopt a bent conformation that could 
nevertheless be directed into clusters on the cell surface. Treat-
ment of the LT 51-expressing cells during spreading with 
DTT restored 9EG7 staining (Fig. 4 B).
The same cells were co-stained with SNAKA51 to detect the 
ligand-bound conformation of 51 and quantitative analysis 
of the fluorescence intensity of 5CFP, 1YFP, and SNAKA51 
staining performed. The intensity profile across adhesion com-
plexes for cells transfected with WT 51 (Fig. 4 D) revealed 
an increase in intensity in all three channels representing 5CFP, 
1YFP, and SNAKA51. This indicates that the WT integrin is 
in an extended, ligand-bound conformation in which the inte-
grin legs are likely to be separated. In contrast, while there was 
a clear increase in intensity in 5CFP and 1YFP over the inte-
grin clusters in the cells expressing LT integrin, the staining 
intensity for SNAKA51 was very low. Quantitation of the 
ratio of SNAKA51 to total 5CFP intensities showed a highly 
significant decrease in SNAKA51 binding in the LT receptor 
(Fig. 4 E) which, like 9EG7 staining, was restored upon addi-
tion of DTT. These results confirm that the LT 5CFP1YFP is 
in an inactive, nonligand-bound state but is still able to form 
clusters in the cell.
GD25 cells express endogenous mouse 5, which could 
be available to pair with the transfected human 1. Immuno-
cytochemical analysis with a mouse-specific anti-5 antibody 
showed some colocalization of mouse 5 with 1YFP in these 
clusters (Fig. S4 A), but because 9EG7 staining remained low, it 
is likely that it had little effect on the results obtained. However, 
to eliminate any contribution from mouse integrins, GD25 cells 
expressing WT or LT 51 were plated onto a human 51-
specific ligand, the cyclic peptide-IgG conjugate CRRETAWAC-
IgG (Humphries et al., 2000). Although CRRETAWAC-IgG is 
a much less potent ligand than FN (Fig. S4 B), 12% (±1%) of 
epitope is not dependent on the conformation of the integrin   
receptor (Fig. S1 A). In the absence of acceptor, the mean fluores-
cence donor lifetime was 2,588 ± 183 picoseconds (ps; mean ± 
SD) within adhesion complexes and 2,505 ± 220 ps in the rest 
of the cell membrane (Fig. 3, D and F). The C18DiD was found 
to label HFF cell membranes uniformly within the areas of 
measurement (Figs. 3 E and Fig. S1 B), indicating that cluster-
ing of the integrin receptors did not interfere with the distribu-
tion of the acceptor. The density of acceptor in the cell membrane 
of the cell illustrated in Fig. 3 E was calculated to be 0.937   
acceptors per unit area (R0
2) and in the presence of acceptor, the 
donor lifetime was reduced to 1,779 ± 190 ps within adhesion 
complexes and to 1,198 ± 127 ps in the adjacent cell membrane 
(Fig. 3, A, C, and F). This finding is indicative of a lower   
efficiency of FRET at the same acceptor density, and therefore 
a greater distance between the donor-labeled integrin headpiece 
and  the  acceptor-labeled  cell  membrane. Assuming  that  the 
VC5-Fab-Alexa 546 adopts the same orientation relative to   
integrin molecules inside and outside of adhesion complexes, 
this infers that the integrin molecules were in a more extended 
conformation inside adhesion complexes.
As stated above, FRET efficiency can vary with acceptor 
concentration due to the different numbers of acceptors avail-
able to the donors as FRET partners; therefore, similar mea-
surements were made over several cells with a range of acceptor 
densities and a consistent difference was found between the 
FRET efficiency adjacent to and within adhesion complexes 
(Fig. 3 G). These results indicate that there is decreased FRET 
efficiency between donor and acceptor within adhesion com-
plexes and demonstrates that 51 in these complexes is in a 
more extended form than that in the adjacent plasma membrane.
To eliminate the possibility that the lower FRET efficien-
cies observed in adhesion complexes were due to an artifact 
arising from a higher concentration of donor molecules that 
could compete with each other for the available acceptors, two 
separate control experiments were performed. Initially, the   
Alexa 546 fluorescence was reduced by photobleaching before 
measuring lifetimes. This had no effect on the difference in life-
times seen within and outside adhesion complexes (Fig. S2 A). 
To confirm this observation, cells were labeled with VC5- 
Fab-Alexa 546 together with increasing proportions of un-
labeled VC5-Fab fragments to reduce the number of fluorescent 
donor molecules available for FRET. Again, no significant effect 
on lifetimes was observed (Fig. S2 B). We therefore conclude 
that the decreased FRET efficiency observed between the mole-
cules in adhesion complexes was due to an increased average 
separation between donor and acceptor. These results provide 
strong evidence that ligand-bound 51 adopts an extended 
conformation compared with unligated receptor.
Restraining leg separation perturbs 51 
function in vivo
The experiments using soluble integrin in Figs. 1 and 2 indicate 
that restraining the legs of soluble 51-Fc affects its confor-
mation and activity. To examine the effect of restraining the legs 
on the function of this integrin in a cellular context, both WT 
and LT full-length 51 were expressed in 1-null GD25 cells 897 Integrin extension at focal adhesions • Askari et al.
demonstrates that restraining integrin 51 subunit separation 
on the cell surface abrogates cell spreading and severely dis-
rupts integrin function. Therefore, cell spreading and adhesion 
complex formation in adherent cells requires 51-integrin to be 
in an extended conformation and one in which leg movement 
can occur.
GD25 cells expressing WT51 formed adhesion complexes 
that were both 9EG7 and SNAKA51 positive. In contrast, cells 
expressing LT 51 not only did not form adhesion com-
plexes, but also failed to spread properly on the peptide ligand 
(cell area = 623 ± 121 µm
2 compared with 1,448 ± 458 µm
2 
for cells expressing WT receptor; P < 0.001; Fig. 5). This result 
Figure  3.  TCSPC-FLIM–based  FRET  analysis  of 
conformation  differences  of  integrin  51  in  HFF 
cells  spread  on  FN.  Representative  HFF  cells 
spread on FN and stained with Alexa 546-VC5-
Fab fragment (the donor, panels A and B) either 
with (top row) or without (bottom row) fluorescent 
membrane stain DiD (the acceptor). C and D show 
false-colored  FLIM  images  representing  donor 
fluorescence lifetimes from individual pixels. Short 
lifetimes are located toward the red end and long   
lifetimes toward the blue end of the spectrum.   
(E) DiD staining. (F) Average lifetimes (in picosec-
onds; ps) of Alexa 546 fluorescence measured in 
adhesions complexes (FA) and in areas between 
adhesion complexes in the cell membrane of the 
cells illustrated in A and B. n = 50 measurements   
each  from  each  cell,  error  bars  indicate  ±SD   
(*, P < 0.001; t test). (G) Graph showing FRET 
efficiencies over a range of acceptor densities in 
different cells within adhesion complexes (triangles)   
and  in  the  adjacent  cell  membrane  (squares).   
n = >20 measurements from each of 12 cells. 
Error bars indicate ±SD.JCB • VOLUME 188 • NUMBER 6 • 2010   898
Figure 4.  Restraining leg separation perturbs 51 function in vivo. (A) 1-integrin was immunoprecipitated from lysates of GD25 cells expressing either 
WT or LT 5CFP1YFP 24 h after transfection, followed by immunoblotting for integrin 5 (antibody H-104; Santa Cruz Biotechnology, Inc.). Black arrow-
head indicates a 300-kD band corresponding to LT integrin, which dissociates upon reduction into component subunits (gray arrowhead). Numbers to the 
left of the gel indicate position of Mr markers. (B) GD25 cells expressing WT or LT 5CFP1YFP co-stained with 9EG7-Alexa 647 to detect active integrin. 
Cells were treated with 1 mM DTT during spreading where indicated. Bar, 10 µm. (C) Quantification of the ratio of fluorescence intensities of 9EG7 staining 
to total 1YFP in 1-integrin clusters. n = fluorescence intensity measurements of 100 clusters from at least 10 cells for each condition. Error bars indicate 
±SD. (D) The same cells were co-stained with SNAKA51-Alexa 555 to detect ligand-bound 51. The fluorescence intensity profiles depict the area of the   
yellow line drawn in image overlays and compare the fluorescence intensities of total 1 (1-YFP; green), total 5 (5-CFP; blue), and SNAKA51 (red).   
(E) Quantification of the ratio of fluorescence intensities of SNAKA51 staining to total 5-CFP in 1-integrin clusters. n = fluorescence intensity measure-
ments of 100 clusters from at least 10 cells for each condition. Error bars indicate ±SD. Bar, 10 µm.899 Integrin extension at focal adhesions • Askari et al.
The data for mAb and ligand binding to the recombinant 
51-Fc  compared  with  cell-based  measurements  exhibited 
some degree of incongruity, which is a reflection of the disparity 
of the two experimental systems. The Fc domain of the inte-
grin fusion protein constructs includes 14 residues of the upper 
hinge and hinge regions of the human 1 constant domains 
(Ridgway et al., 1996), which may introduce a degree of flexi-
bility in these constructs that is not seen on cellular integrin. It 
is likely that the epitopes for the mAbs tested are much more 
accessible in the recombinant receptor than in whole integrin 
expressed on the cell surface, and this may have led to apparent 
differences in their levels of binding (in particular for SNAKA51 
and 8E3). In addition, although restricting leg movement had a 
dramatic effect on cell adhesion, ligand binding to the recombi-
nant construct was less strikingly modulated by the leg con-
straint. It is possible that even though the LT receptor is bent, 
the ligand-binding pocket is accessible to the small fragment of 
FN used in this assay, particularly as the presence of manganese 
ions could prime the ligand-binding pocket independently of 
other activation-associated conformational changes.
Our results clearly show that SNAKA51 is a reporter of 
ligand-bound 51 which, on available evidence, adopts a con-
formation in which the leg regions are apart (Takagi et al., 2002; 
Kim et al., 2003; Zhu et al., 2007). We therefore infer that this 
antibody also reports leg separation; an assumption that is   
supported by our data because binding of SNAKA51 to LT 
51 expressed on GD25 cells was very low.
Ligand binding is accompanied by an opening of the   
integrin headpiece by hybrid domain swing-out (Mould et al., 
2003a; Xiao et al., 2004). Using recombinant integrin, we have 
demonstrated that hybrid domain swing-out is directly coupled 
to leg separation and that prevention of the latter abrogates 
conformational changes associated with activation and ligand   
binding. In vivo, destabilization of the integrin transmembrane 
or cytoplasmic domain association by mutation (Hughes et al., 
1996; Luo et al., 2004) or the binding of talin (Wegener et al., 
Discussion
The results of this study have extended the current model of con-
formational changes in integrin activation to include 1-integrins 
on adherent cells. Our results provide strong evidence that a 
close interaction of the membrane-proximal extracellular do-
mains is necessary to maintain the receptor in a low affinity state. 
Once ligated to ligand and clustered in adhesion complexes, the 
integrin is in an extended conformation where the legs are sep-
arated. Integrin in which leg movement is constrained cannot 
mediate efficient cell spreading.
An important finding of this study was to pinpoint the 
9EG7 epitope to aspartate 522 in I-EGF-2 located in the knee 
region of the -subunit. The epitope of 9EG7 mimics almost 
exactly that of the anti-2 mAb KIM127, which incorporates 
residues 504–508 of the 2-subunit (Lu et al., 2001). KIM127 
has been proven through structural studies to report an integrin 
extension event that correlates with activation (Beglova et al., 
2002; Shi et al., 2007). Therefore, we conclude that binding   
of 9EG7  similarly  reports  extended  conformations  of  1- 
integrins and binding of this antibody stabilizes an active form 
of the receptor.
Cell-based  flow  cytometry  assays  demonstrate  that  the 
9EG7 epitope is exposed on unstimulated HFF cells, which im-
plies a degree of spontaneous 1 extension. This finding is in 
contrast to KIM127, whose binding to leukocytes is very low in 
the absence of stimulation by agonists (Lu et al., 2001). In turn, 
this suggests a less rigid control of the activity of the 1-integrins, 
which may be a reflection of their role as mediators of steady-
state cell–ECM binding, compared with the 2 and 3 receptors 
that need to exhibit a rapid response to injury from their default 
inactive state (Shattil et al., 1998). However, this may not neces-
sarily be reflected across all cell types. Specific cellular functions 
may dictate the control of integrin conformational changes, par-
ticularly as different ligands appear to induce diverse conformers 
of 1-integrin heterodimers (Bazzoni et al., 1998).
Figure 5.  Spreading of GD25 cells express-
ing WT or LT 51 on CRRETAWAC-IgG. GD25   
cells  transiently  expressing  either  WT  or  LT   
5CFP1YFP  were  allowed  to  spread  on 
CRRETAWAC-IgG for 60 min, fixed, and stained 
with 9EG7-Alexa 647 and SNAKA51-Alexa 555.   
(A and D) 1-YFP fluorescence; (B and E) 9EG7 
staining; (C) SNAKA51 staining. Bar, 10 µm.JCB • VOLUME 188 • NUMBER 6 • 2010   900
donor alone may suggest that a proportion of receptor is not 
fully extended. FRET between fluorophores occurs when they 
are within a distance of 10 nm and the distance of the integrin 
headpiece  to  the  membrane  in  a  fully  extended  receptor  is   
almost double this, implying that lower affinity receptor is pres-
ent in adhesion complexes. Some studies have attempted to 
measure absolute distances of the distance between the integrin 
headpiece and the cell membrane (Chigaev et al., 2003; Coutinho 
et al., 2007), but at best these provide only an average measure-
ment from across the whole cell. Importantly, the FLIM method 
used in the present study, while again measuring average FRET 
efficiencies, allows sampling from different areas within the 
same cell and provides a more detailed survey of integrin con-
formations present on the cell surface. The results provide 
strong  evidence  that  extended  51-integrin  is  enriched  in   
adhesion complexes.
Materials and methods
Antibodies and reagents
Antibodies binding to human 1-integrin were 9EG7 (a gift of D. Westweber, 
Max Planck Institute for Molecular Biomedicine, Munster, Germany), 
HUTS4 (Millipore), K20 (Beckman Coulter), 12G10 (Mould et al., 1995), 
and 8E3 (Mould et al., 2005). Antibodies recognizing human 5 were 
mAb11 (a gift of K. Yamada, National Institute of Dental and Craniofacial 
Research, NIH, Bethesda, MD), VC5 (a gift of R. Isberg, Tufts University 
Medical School, Boston, MA), and SNAKA51 (Clark et al., 2005). Fab 
fragments  of  VC5  were  produced  by  ficin  cleavage  of  purified  IgG   
followed by removal of Fc-containing fragments using protein A–Sepharose, 
according to the manufacturer’s instructions (Thermo Fisher Scientific). Di-
rect labeling of antibodies with Alexa Fluor fluorophores was performed 
using an antibody-labeling kit according to the manufacturer’s instructions 
(Invitrogen). Vybrant C18DiD was also from Invitrogen.
Bovine plasma FN and laminin were purchased from Sigma-Aldrich, 
and the recombinant 50K fragment of FN comprising type III repeats 6–10 
was made as described previously (Mould et al., 1997). The Cys-Arg-Arg-
Glu-Thr-Ala-Trp-Ala-Cys (CRRETAWAC) peptide was purchased from Pep-
tide 2.0 Inc. and was cyclized before conjugating to rabbit IgG using BS
3 
(bis[sulfosuccinimidyl]  suberate;  Thermo  Fisher  Scientific)  as  described   
previously (Humphries et al., 2000). The production of recombinant solu-
ble 51-Fc has been described previously (Coe et al., 2001). The 5-Fc 
and 1-Fc used in these experiments comprised residues 1–951 of 5, and 
residues 1–708 of 1 and each subunit was fused to a human Fc domain 
mutated to facilitate heterodimerization of the subunits. To allow removal of 
the Fc domain, a Tobacco Etch Virus (TEV) cleavage site was included   
between the integrin sequence and the Fc domain in the 1 construct only. 
If required, the integrin was purified on protein A–Sepharose (GE Health-
care) and the Fc domain removed from the  subunit with TEV protease   
(Invitrogen) according to the manufacturer’s instructions.
Full-length 5CFP cDNA was provided by A.R. Horwitz (University 
of Virginia, Charlottesville, VA). 1YFP was obtained by cloning the 1 
cDNA from 1-GFP (Parsons et al., 2008) into a pCDNA3 vector contain-
ing eYFP. Mutation of both soluble and full-length 51 was performed by 
site-directed mutagenesis using QuikChange XL kit (Agilent Technologies) 
according to the manufacturer’s instructions.
HFFs (provided by K. Clark, University of Leicester, UK) and GD25 
cells (provided by R. Fässler, Max Planck Institute for Biochemistry, Martin-
sried, Germany) were maintained in Dulbecco’s minimal essential medium 
(Sigma-Aldrich) supplemented with 10% fetal calf serum and 2 mM l-gluta-
mine. GD25 cells were transfected with plasmid DNA using Lipofectamine 
2000 reagent (Invitrogen) according to the manufacturer’s instructions.
Fc-capture ELISA to compare epitope expression and ligand binding by 
51-Fc heterodimers
Binding of antibodies and 50K ligand to soluble 51-Fc proteins was 
performed by Fc-capture ELISA as described previously (Mould et al., 
2003a). In brief, 96-well plates (Costar) were coated with goat anti– 
human 1 Fc (Jackson Immunochemicals) then blocked with 5% (wt/vol) BSA 
in Tris-buffered saline (TBS). Tissue culture supernatant from integrin-transfected 
2007) activates integrin and is likely to facilitate to hybrid 
movement (Takagi et al., 2001). However, the extent of the   
contribution  of  outside-in  and  inside-out  events  to  integrin 
conformational changes and particularly hybrid domain move-
ment is difficult to dissect and remains unclear. At present, 
there  is  more  evidence  to  suggest  that  outside-in  signaling 
plays  a  greater  role  in  this  conformational  change  (Mould   
et al., 2003b; Takagi et al., 2003; Xiao et al., 2004). However, 
global  shape  changes  are  a  result  of  a  fine  balance  of  the   
equilibrium between protein–integrin binding events on both 
sides of the cell membrane. In adherent cells, the contribution 
of forces to the formation and stabilization of specific integrin 
conformations is an area of increasing interest. There is evi-
dence that application of force can increase the rate of forma-
tion and the lifetime of integrin–ligand bonds. Modeling data 
have predicted this to occur by stabilizing the ligand-bound 
high affinity conformation (Puklin-Faucher et al., 2006; Zhu   
et al., 2008), and experimental data have demonstrated strength-
ening  of  these  interactions  by  the  formation  of  catch  bonds 
(Friedland et al., 2009; Kong et al., 2009). Previous work using 
IIb3 has suggested that force is required for receptor exten-
sion (Zhu et al., 2008), whereas our results indicate that some 
degree of spontaneous unbending occurs for 51. This appar-
ent contradiction could be a reflection of the diversity of con-
formational control mechanisms that characterize individual 
integrin receptors. It remains to be determined whether force is 
needed to stabilize an extended integrin, but very recent work 
has indicated that the binding of talin to IIb3 tethered in lipid 
nanodiscs is sufficient to activate and extend the receptor in the 
absence of force (Ye et al., 2010). We speculate that for 51 the 
application of force may contribute to the stability of an extended 
receptor and to facilitate subsequent hybrid domain movement.
Previous  studies  using  integrins  with  constrained  leg 
movement  have  been  restricted  to  either  soluble  constructs 
(Takagi et al., 2001) or full-length integrin on cells in suspen-
sion (Luo et al., 2004; Kamata et al., 2005). By expressing LT 
51 in GD25 cells, we have been able to gain further insight 
to the role of conformational changes in adherent cell function. 
Cells expressing LT 51 were unable to form proper FAS, but 
did appear in clusters on the cell surface if nonconstrained re-
ceptor was present. This observation suggests that low affinity 
integrin could be a component of adhesion complexes. Whether 
this is true under normal circumstance is not known, and al-
though it can be envisaged that having a pool of readily avail-
able inactive receptor might be beneficial to the cell, existing 
evidence suggests that clustering of integrin only occurs after 
integrin activation and ligand binding (Kim et al., 2004; Cluzel 
et al., 2005). It is possible that the LT 51, although 9EG7 
negative,  is  sufficiently  unbent  to  bind  ligand  and  therefore 
cluster, but not to initiate downstream signaling pathways lead-
ing to cell spreading, which requires leg separation (Zhu et al., 
2007). A very recent study has suggested that IIb3 clusters in 
response to talin binding without a concomitant increase in the 
affinity of the integrin (Bunch, 2010), implying that low affinity 
receptor is a component of some integrin adhesion complexes.
The reduction in the donor fluorescence lifetime in adhe-
sion complexes in the presence of acceptor compared with   901 Integrin extension at focal adhesions • Askari et al.
FRET efficiencies were calculated from the measured donor life-
times using the equation EFRET = 1  (DA/D), where DA and D are the 
mean donor lifetimes in the presence and absence of acceptor, respec-
tively. The Förster radius, R0 (the separation of a single donor and accep-
tor at which the FRET efficiency is 0.5) for Alexa 546 and C18DiD was 
calculated to be 6.6 nm using spectral data obtained from Invitrogen and 
the value of the orientation factor corresponding to the dynamic aver-
aging limit. The steady-state anisotropy of C18DiD molecules in lipid vesi-
cles  was  measured  using  an  L-format  Jobin-Yvon  Fluorolog  fluorimeter 
with a Xenon lamp as a light source and found to be 0.154 compared 
with  the  maximum  possible  value  for  static  dye  molecules  of  0.4   
(Lakowicz, 1983), indicating free rotation of the DiD dye molecules. For 
FRET pairs where both fluorophores exhibit anisotropies <0.22, the error 
introduced by using the dynamic averaging value to calculate the Förster 
radius is <10% (Haas et al., 1978). The dye/protein (f:p) molar ratio of 
the labeled Fabs was calculated to be almost equal at 1.18 fluorophore:1 
of Fab fragment.
To  determine  acceptor  densities  from  the  measured  fluorescence   
intensity of C18DiD, FLIM-FRET measurements were performed on samples 
of C18DiI (donor) and C18DiD (acceptor) randomly distributed in a mono-
layer of phosphatidylcholine. The acceptor was purposely photobleached 
to obtain a plot of EFRET versus acceptor fluorescence intensity. These data 
were fitted to the FRET efficiency as a function of acceptor density for a 
zero distance of closest approach of donors and acceptors calculated by 
Wolber and Hudson (1979), EFRET = 1  (0.6463e
4.7497D + 0.3537e
20168D) 
and D = KI, where K is a constant factor relating the fluorescence intensity, 
I and acceptor density, D (in units of acceptors per R0
2). The value of K 
found was then used to calculate acceptor densities from the measured 
C18DiD intensities, an approach that has been used previously (Carraway 
et al., 1990; Chigaev et al., 2003).
Statistical analysis
The Student’s t test was used to test statistical significance between two 
groups of data and values <0.05 were taken as significant.
Online supplemental material
Fig. S1 A shows the ratio of VC5–Alexa 546 fluorescence to 5CFP   
fluorescence in WT and LT 51 at different locations. Fig. S1 B shows 
the fluorescence intensity of DiD staining in focal adhesions and the cell 
membrane. Fig. S2 shows the effect of both photobleaching and increas-
ing proportions of unlabeled VC5 on the lifetime of VC5–Alexa 546 in 
adhesion complexes and the cell membrane. Fig. S3 shows flow cytom-
etry analysis of the conformation of LT 51 assessed by 9EG7 binding. 
Fig. S4 A shows the localization of mouse 5 to adhesion complexes in 
GD25 cells expressing WT or LT 51. Fig. S4 B shows the spreading 
of HFF cells on CRRETAWAC-IgG. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200907174/DC1.
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cells  was  added  and  incubated  at  room  temperature  for  1  h.  The   
plate was then washed with TBS and 10 µg/ml of primary antibody 
added. After a further 45 min incubation, the plate was washed again 
and the bound antibody quantitated by addition of 1:1,000 anti–mouse 
or anti–rat IgG peroxidase conjugate (Jackson Immunochemicals) followed 
by 2,2-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) substrate (ABTS; 
Sigma-Aldrich). Absorbance was read at 405 nm. For experiments mea-
suring ligand binding to WT and mutant 51-Fc constructs, 50K frag-
ment of FN was biotinylated using sulfo-long chain-N-hydroxysuccinimido 
biotin (Thermo Fisher Scientific) as described previously (Mould et al., 
1997) and used at 0.5 µg/ml, either with or without the addition of acti-
vating anti-5 or 1 antibodies at 10 µg/ml. Binding of ligand was quan-
titated by adding 1:500 extravidin-peroxidase conjugate (Sigma-ALdrich) 
followed by ABTS as above. Background binding to wells incubated with 
supernatant from mock-transfected cells was subtracted from all measure-
ments. In assays involving a comparison between different 51-Fc integrin 
constructs, binding levels of the neutral anti-1 antibody K20 were used 
to normalize for any differences between the amounts of integrin hetero-
dimers bound to the wells as described previously (Mould et al., 2003a).
Immunofluorescence
Cells were plated onto glass-bottom dishes (MatTek) precoated with ligand 
and allowed to spread for 60 min in serum-free culture medium. Transiently 
transfected GD25 cells were used 24–36 h after transfection. Cells were 
fixed with 3% (wt/vol) paraformaldehyde for 15 min, permeabilized for 
5 min with 0.5% (wt/vol) Triton X-100 (Sigma-Aldrich), and subsequently   
incubated for 45 min with the appropriate Alexa Fluor antibody conjugate. 
After washing in PBS, cells were imaged at room temperature using a Delta-
Vision system (Applied Precision) comprising a widefield inverted micro-
scope (model IX-70; Olympus) with a 100x/1.35 UPLAN APO objective. 
Images were captured using a CCD camera (model CH350; Photometrics) 
and Softworx analysis software (Applied Precision). Subsequent image 
analysis and processing were performed using ImageJ and Adobe Photo-
shop software. For assays using CRRETAWAC-IgG as ligand, the plates 
were coated with 100 µg/ml of the peptide ligand and blocked with   
10 mg/ml heat-denatured bovine serum albumin (Sigma-Aldrich) before   
addition of cells.
FLIM-based FRET analysis
HFFs were allowed to spread on FN-coated glass-bottom dishes (MatTek) 
for 1 h in serum-free medium and then for a further 15 min in the presence 
of Vybrant C18DiD at a final concentration of 5 µM to label the cell mem-
brane. The cells were washed and fixed with 3% (wt/vol) PFA and stained 
with a Fab fragment of VC5 directly conjugated to Alexa Fluor 546 as de-
scribed above. C18DiD and Alexa 546 have single photon absorption and 
fluorescence emission spectra sufficiently separated so that their fluores-
cence can be excited and detected separately while an overlap between 
the emission spectrum of Alexa 546 and the absorption spectrum of C18DiD 
allows these two dyes to act as a FRET pair.
Fluorescence  lifetime  images  of  Alexa  Fluor  546–labeled  cells,   
either with or without acceptor (DiD), were acquired at room temperature 
using a purpose-built laser scanning confocal microscope equipped with 
time-correlated single photon counting (TCSPC) electronics (SPC-730, Becker-
Hickl GmbH). The microscope incorporated an inverted microscope body 
(Axiovert 135; Carl Zeiss, Inc.) with a 40x/1.3NA FLUAR objective (Carl 
Zeiss, Inc.), and was used to acquire both FLIM and intensity images. 
Alexa 546 was excited with 545-nm pulsed laser light (Coherent, MIRA-
OPO, 76-Mhz repetition rate) and the Alexa 546 fluorescence was de-
tected  at  560–610  nm  using  a  fast  photomultiplier  tube  (PMC-100; 
Becker-Hickl GmbH). The resulting time-resolved images were analyzed 
using SPCImage (Becker-Hickl GmbH) FLIM analysis software. Fluorescent 
intensity decays were fitted to a single exponential decay model where 
acceptor was absent and a bi-exponential model when both donor and ac-
ceptor were present, to extract mean lifetimes. The reduced 
2 parameter was 
used to judge the goodness of fit, which was deemed acceptable for 0.8 < 
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